NASDAQ:FGEN FibroGen - FGEN Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding FibroGen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $18.81 +0.10 (+0.53%) (As of 03/28/2023 12:00 AM ET) Add Compare Share Share Today's Range$18.64▼$18.9650-Day Range$18.15▼$25.1852-Week Range$7.81▼$25.69Volume471,636 shsAverage Volume1.03 million shsMarket Capitalization$1.77 billionP/E RatioN/ADividend YieldN/APrice Target$23.40 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability FibroGen MarketRank™ ForecastAnalyst RatingHold2.40 Rating ScoreUpside/Downside24.4% Upside$23.40 Price TargetShort InterestBearish5.55% of Float Sold ShortDividend StrengthN/ASustainability-0.84Upright™ Environmental ScoreNews Sentiment0.67Based on 7 Articles This WeekInsider TradingSelling Shares$2.06 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.75) to ($2.16) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.11 out of 5 starsMedical Sector488th out of 999 stocksPharmaceutical Preparations Industry231st out of 489 stocks 3.2 Analyst's Opinion Consensus RatingFibroGen has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on 3 buy ratings, 1 hold rating, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $23.40, FibroGen has a forecasted upside of 24.4% from its current price of $18.81.Amount of Analyst CoverageFibroGen has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 1.0 Short Interest Percentage of Shares Shorted5.55% of the float of FibroGen has been sold short.Short Interest Ratio / Days to CoverFibroGen has a short interest ratio ("days to cover") of 5.2.Change versus previous monthShort interest in FibroGen has recently increased by 20.15%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldFibroGen does not currently pay a dividend.Dividend GrowthFibroGen does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreFibroGen has received a 74.19% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Clinical research services for the autoimmune system", "Clinical research services for cancer", and "Clinical research services for deficiency diseases" products. See details.Environmental SustainabilityThe Environmental Impact score for FibroGen is -0.84. Previous Next 2.0 News and Social Media Coverage News SentimentFibroGen has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for FibroGen this week, compared to 2 articles on an average week.MarketBeat FollowsOnly 1 people have added FibroGen to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, FibroGen insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,056,205.00 in company stock.Percentage Held by InsidersOnly 2.82% of the stock of FibroGen is held by insiders.Percentage Held by Institutions76.89% of the stock of FibroGen is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for FibroGen are expected to grow in the coming year, from ($2.75) to ($2.16) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of FibroGen is -5.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of FibroGen is -5.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About FibroGen (NASDAQ:FGEN) StockFibroGen, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. It focuses on the hypoxia-inducible factor and connective tissue growth factor biology to develop medicines for the treatment of anemia, fibrotic disease, and cancer. The company was founded by Thomas B. Neff on September 29, 1993 and is headquartered in San Francisco, CA.Read More Receive FGEN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for FibroGen and its competitors with MarketBeat's FREE daily newsletter. Email Address FGEN Stock News HeadlinesMarch 21, 2023 | marketbeat.comWhy did Sarepta Therapeutics Stock Plummet? (FGEN)SRPT stock fell 20% after the FDA changed course on their new DMD treatment approval. The stock remains strong with an encouraging outlook and a mod Buy rating.March 24, 2023 | finance.yahoo.comFibroGen (NASDAQ:FGEN investor five-year losses grow to 60% as the stock sheds US$145m this past weekMarch 29, 2023 | Press Research (Ad)Lithium Could Be 2023's Next Big SurpriseLithium is the hottest commodity for our green futureMarch 15, 2023 | markets.businessinsider.comRaymond James Reaffirms Their Buy Rating on FibroGen (FGEN)March 11, 2023 | finance.yahoo.comFibroGen, Inc. (NASDAQ:FGEN) Q4 2022 Earnings Call TranscriptFebruary 27, 2023 | finance.yahoo.comFibroGen Reports Fourth Quarter and Full Year 2022 Financial ResultsFebruary 27, 2023 | finance.yahoo.comFibroGen (FGEN) Reports Q4 Loss, Tops Revenue EstimatesFebruary 27, 2023 | finance.yahoo.comFibroGen to Present at Cowen’s 43rd Annual Health Care ConferenceMarch 29, 2023 | Press Research (Ad)Lithium Could Be 2023's Next Big SurpriseLithium is the hottest commodity for our green futureFebruary 26, 2023 | msn.comEarnings Preview For FibroGenFebruary 23, 2023 | finance.yahoo.comShould You Buy FibroGen (FGEN) Ahead of Earnings?February 20, 2023 | finance.yahoo.comFibroGen (FGEN) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 ReleaseFebruary 17, 2023 | finance.yahoo.comFibroGen to Report Fourth Quarter and Full Year 2022 Financial ResultsFebruary 2, 2023 | finance.yahoo.comFibroGen to Present at SVB Securities Global Biopharma ConferenceJanuary 16, 2023 | finance.yahoo.comWith 73% ownership in FibroGen, Inc. (NASDAQ:FGEN), institutional investors have a lot riding on the businessNovember 28, 2022 | finance.yahoo.comFibroGen to Participate at Bank of America 2022 Biotech SMID Cap Virtual ConferenceNovember 9, 2022 | finance.yahoo.comFibroGen Third Quarter 2022 Earnings: Misses ExpectationsNovember 7, 2022 | finance.yahoo.comFibroGen Announces $50 Million Royalty Monetization Financing with NovaQuest Capital ManagementNovember 7, 2022 | finance.yahoo.comFibroGen (FGEN) Reports Q3 Loss, Misses Revenue EstimatesNovember 1, 2022 | finance.yahoo.comFibroGen to Participate at Stifel 2022 Healthcare ConferenceNovember 1, 2022 | finance.yahoo.comEarnings Preview: FibroGen (FGEN) Q3 Earnings Expected to DeclineOctober 24, 2022 | finance.yahoo.comFibroGen to Report Third Quarter 2022 Financial ResultsOctober 19, 2022 | seekingalpha.comFibroGen - Biotech - Seeking AlphaOctober 15, 2022 | finance.yahoo.comFibroGen (NASDAQ:FGEN) adds US$108m to market cap in the past 7 days, though investors from five years ago are still down 71% - Yahoo FinanceOctober 15, 2022 | finance.yahoo.comFibroGen (NASDAQ:FGEN) adds US$108m to market cap in the past 7 days, though investors from five years ago are still down 71%October 14, 2022 | benzinga.comThinking about buying stock in Reviva Pharmaceuticals, Charge Enterprises, Applied DNA Sciences, Delta Ai - BenzingaOctober 10, 2022 | nasdaq.comFibroGen Reaches Analyst Target Price - NasdaqSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive FGEN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for FibroGen and its competitors with MarketBeat's FREE daily newsletter. Email Address FGEN Company Calendar Last Earnings2/27/2023Today3/29/2023Next Earnings (Estimated)5/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:FGEN CUSIPN/A CIK921299 Webwww.fibrogen.com Phone(415) 978-1200Fax415-978-1902Employees566Year FoundedN/APrice Target and Rating Average Stock Price Forecast$23.40 High Stock Price Forecast$35.00 Low Stock Price Forecast$14.00 Forecasted Upside/Downside+24.4%Consensus RatingHold Rating Score (0-4)2.40 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($3.14) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-293,650,000.00 Net Margins-208.66% Pretax Margin-209.52% Return on Equity-338.94% Return on Assets-44.30% Debt Debt-to-Equity RatioN/A Current Ratio1.80 Quick Ratio1.65 Sales & Book Value Annual Sales$140.73 million Price / Sales12.59 Cash FlowN/A Price / Cash FlowN/A Book Value($0.02) per share Price / Book-940.50Miscellaneous Outstanding Shares94,183,000Free Float91,527,000Market Cap$1.77 billion OptionableOptionable Beta0.85 Key ExecutivesEnrique A. ConternoChief Executive Officer & DirectorJuan GrahamChief Financial Officer & Senior Vice PresidentElias KouchakjiSenior VP-Clinical Development & Drug SafetyMark EisnerChief Medical Officer & Executive Vice PresidentJohn HunterChief Scientific OfficerKey CompetitorsAmphastar PharmaceuticalsNASDAQ:AMPHAkero TherapeuticsNASDAQ:AKROCatalyst PharmaceuticalsNASDAQ:CPRXPacira BioSciencesNASDAQ:PCRXSchrödingerNASDAQ:SDGRView All CompetitorsInsiders & InstitutionsThane WettigSold 905 sharesTotal: $16,932.55 ($18.71/share)Enrique A ConternoSold 31,589 sharesTotal: $638,097.80 ($20.20/share)Christine ChungSold 7,606 sharesTotal: $153,641.20 ($20.20/share)Mark EisnerSold 10,140 sharesTotal: $204,828.00 ($20.20/share)Juan GrahamSold 4,912 sharesTotal: $99,222.40 ($20.20/share)View All Insider TransactionsView All Institutional Transactions FGEN Stock - Frequently Asked Questions Should I buy or sell FibroGen stock right now? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for FibroGen in the last twelve months. There are currently 1 sell rating, 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" FGEN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in FGEN, but not buy additional shares or sell existing shares. View FGEN analyst ratings or view top-rated stocks. What is FibroGen's stock price forecast for 2023? 5 equities research analysts have issued twelve-month price targets for FibroGen's stock. Their FGEN share price forecasts range from $14.00 to $35.00. On average, they predict the company's stock price to reach $23.40 in the next twelve months. This suggests a possible upside of 24.4% from the stock's current price. View analysts price targets for FGEN or view top-rated stocks among Wall Street analysts. How have FGEN shares performed in 2023? FibroGen's stock was trading at $16.02 at the beginning of the year. Since then, FGEN stock has increased by 17.4% and is now trading at $18.81. View the best growth stocks for 2023 here. Are investors shorting FibroGen? FibroGen saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 4,830,000 shares, an increase of 20.1% from the February 28th total of 4,020,000 shares. Based on an average daily trading volume, of 929,100 shares, the days-to-cover ratio is presently 5.2 days. Approximately 5.6% of the company's shares are short sold. View FibroGen's Short Interest. When is FibroGen's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 8th 2023. View our FGEN earnings forecast. How were FibroGen's earnings last quarter? FibroGen, Inc. (NASDAQ:FGEN) announced its quarterly earnings data on Monday, February, 27th. The biopharmaceutical company reported ($0.70) earnings per share for the quarter, topping analysts' consensus estimates of ($0.95) by $0.25. The biopharmaceutical company earned $34.40 million during the quarter, compared to the consensus estimate of $23.95 million. FibroGen had a negative net margin of 208.66% and a negative trailing twelve-month return on equity of 338.94%. The company's revenue for the quarter was up 108.0% compared to the same quarter last year. During the same quarter last year, the firm posted ($1.45) earnings per share. What ETFs hold FibroGen's stock? ETFs with the largest weight of FibroGen (NASDAQ:FGEN) stock in their portfolio include First Trust NYSE Arca Biotechnology Index Fund (FBT), Invesco Dynamic Biotechnology & Genome ETF (PBE), ALPS Medical Breakthroughs ETF (SBIO), Virtus LifeSci Biotech Clinical Trials ETF (BBC), Invesco Nasdaq Future Gen 200 ETF (QQQS), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3x Shares (LABU) and Global X Aging Population ETF (AGNG). What other stocks do shareholders of FibroGen own? Based on aggregate information from My MarketBeat watchlists, some companies that other FibroGen investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), Aegean Marine Petroleum Network (ANW), NIC (EGOV), Gran Tierra Energy (GTE), Allergan (AGN) and ALJ Regional (ALJJ). When did FibroGen IPO? (FGEN) raised $146 million in an initial public offering (IPO) on Friday, November 14th 2014. The company issued 8,100,000 shares at $18.00 per share. Goldman Sachs, Citigroup and Leerink Partners served as the underwriters for the IPO and RBC Capital Markets, Stifel and William Blair were co-managers. What is FibroGen's stock symbol? FibroGen trades on the NASDAQ under the ticker symbol "FGEN." Who are FibroGen's major shareholders? FibroGen's stock is owned by a number of institutional and retail investors. Top institutional investors include Armistice Capital LLC (4.11%), First Trust Advisors LP (3.17%), Schroder Investment Management Group (1.87%), Geode Capital Management LLC (1.76%), Price T Rowe Associates Inc. MD (0.99%) and Eagle Asset Management Inc. (0.96%). Insiders that own company stock include Christine Chung, Enrique A Conterno, Juan Graham, K Peony Yu, Kalevi Kurkijarvi, Mark Eisner, Pat Cotroneo, Thane Wettig and Thomas F Kearns Jr. View institutional ownership trends. How do I buy shares of FibroGen? Shares of FGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is FibroGen's stock price today? One share of FGEN stock can currently be purchased for approximately $18.81. How much money does FibroGen make? FibroGen (NASDAQ:FGEN) has a market capitalization of $1.77 billion and generates $140.73 million in revenue each year. The biopharmaceutical company earns $-293,650,000.00 in net income (profit) each year or ($3.14) on an earnings per share basis. How many employees does FibroGen have? The company employs 566 workers across the globe. How can I contact FibroGen? FibroGen's mailing address is 409 ILLINOIS STREET, SAN FRANCISCO CA, 94158. The official website for the company is www.fibrogen.com. The biopharmaceutical company can be reached via phone at (415) 978-1200, via email at ir@fibrogen.com, or via fax at 415-978-1902. This page (NASDAQ:FGEN) was last updated on 3/29/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.